The Role of PAF in Bronchial Asthma
Author Information
Author(s): R. H. Gundel, H. O. Heuer, L. G. Letts
Primary Institution: Department of Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc.
Hypothesis
Is platelet activating factor (PAF) an important mediator in bronchial asthma?
Conclusion
Based on available clinical studies, platelet activating factor is not a key mediator that can be blocked to provide therapy for human bronchial asthma.
Supporting Evidence
- PAF receptor antagonists showed efficacy in animal models but failed in human studies.
- Clinical studies did not support a major role of PAF in human bronchial asthma.
- PAF antagonists blocked exogenous PAF effects in humans but not allergen-induced responses.
Takeaway
Researchers studied whether a substance called PAF is important in asthma treatment, but found it doesn't help in humans like it does in animals.
Limitations
The relevance of preclinical models to human asthma is unclear, and the complexity of asthma may not be fully captured in these models.
Participant Demographics
Bronchial asthma affects approximately 5-8% of the population.
Want to read the original?
Access the complete publication on the publisher's website